# Steering the next generation of NCI-sponsored clinical trials in gastroesophageal cancers

> **NIH NIH R50** · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $78,951

## Abstract

Gastrointestinal cancers, and gastroesophageal adenocarcinomas in particular, are
experiencing a clinical renaissance with the approval of recent biomarker-directed
therapies. With the clinical advances comes multiple new questions for the field, many
of which the NCI-sponsored clinical trials infrastructure is optimally suited to address.
As a leader in the NRG non-colorectal committee and recently elected chair of the NCI
Esophagogastric Task Force I am optimally suited, and deeply committed to leveraging
NCI-sponsored clinical trials to address open clinical and scientific questions in
gastroesophageal cancers. I have demonstrated an altruistic dedication to clinical
research and ability to evaluate and implement NCI-trials at my institution where I am PI
and lead accruer to NRG-GI006 and NRG-GI007. I have multiple relevant institutional
roles including program leadership, IRB core membership and broader satellite network
liaison where I lead efforts to extend NCI-sponsored trials to our community sites to
bring trials to patients where they live. A key feature of successful trial implementation
and accrual is appropriate trial selection informed by patient demographics and
appropriate feasibility. With the support of the R50 Research Specialist award I will
expand a novel trial evaluation program to improve implementation of NCI-sponsored
trials at my institution. Through my roles in the NRG and NCI I will pilot this same
program in evaluating developing concepts at the national level. My ultimate goal is to
develop and implement pragmatic trials that address key questions in the field of
gastroesophageal cancers.

## Key facts

- **NIH application ID:** 10942182
- **Project number:** 1R50CA291818-01
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Samuel J Klempner
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $78,951
- **Award type:** 1
- **Project period:** 2024-09-19 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10942182

## Citation

> US National Institutes of Health, RePORTER application 10942182, Steering the next generation of NCI-sponsored clinical trials in gastroesophageal cancers (1R50CA291818-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10942182. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*